Clinical Trial

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-06-13; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2024-07-02
Trial Details
NCT Number NCT06465433
Lead Sponsor Incyte Corporation
Conditions Hematologic Malignancies
Enrollment 25 participants
Start Date 2022-11-08
Primary Completion 2027-08-29 (estimated)
Study Completion 2027-08-29 (estimated)
Updated on ClinicalTrials.gov 2025-12-10